Car-t cells for relapsed b-cell leukemia and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute leukemia or B-cell lymphoma that has not improved with standard treatment or has returned after treatment.
- You are between 14 and 75 years old.
- Your cancer cells have the CD19 protein (confirmed by a lab test).
- You have at least one tumor that can be measured by scans or tests.
- You are generally well enough to do daily activities (ECOG score of 3 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.